

Kay Ka-Wai Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2197426/publications.pdf>

Version: 2024-02-01

34
papers

966
citations

430442

18
h-index

454577

30
g-index

36
all docs

36
docs citations

36
times ranked

1849
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanding the clinical and molecular spectrum of pituitary blastoma. <i>Acta Neuropathologica</i> , 2022, 143, 415-417.	3.9	2
2	Molecular landscape of IDH-wildtype, H3-wildtype glioblastomas of adolescents and young adults. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	0
3	Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas. <i>Laboratory Investigation</i> , 2022, 102, 731-740.	1.7	5
4	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. <i>Frontiers in Oncology</i> , 2022, 12, 839302.	1.3	3
5	RARE-06. Expanding the clinical and molecular spectrum of pituitary blastoma. <i>Neuro-Oncology</i> , 2022, 24, i10-i10.	0.6	0
6	Low-grade BRAF V600E mutant oligodendroglioma-like tumors of children may show EGFR and MET amplification. <i>Brain Pathology</i> , 2021, 31, 211-214.	2.1	2
7	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. <i>Modern Pathology</i> , 2021, 34, 1245-1260.	2.9	21
8	Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106882.	0.6	1
9	IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. <i>Brain Pathology</i> , 2020, 30, 541-553.	2.1	73
10	Radiomic Features From Multi-Parameter MRI Combined With Clinical Parameters Predict Molecular Subgroups in Patients With Medulloblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 558162.	1.3	34
11	Clinical and mutational profiles of adult medulloblastoma groups. <i>Acta Neuropathologica Communications</i> , 2020, 8, 191.	2.4	30
12	Incremental prognostic value and underlying biological pathways of radiomics patterns in medulloblastoma. <i>EBioMedicine</i> , 2020, 61, 103093.	2.7	23
13	Molecular subgrouping of medulloblastoma based on few-shot learning of multitasking using conventional MR images: a retrospective multicenter study. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa079.	0.4	5
14	Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz015.	0.4	22
15	MEDU-05. PROGNOSTIC IMPLICATION OF TERT PROMOTER MUTATION AND TP53 NUCLEAR STAINING IN ADULT MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii104-ii104.	0.6	0
16	Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. <i>Brain Pathology</i> , 2019, 29, 782-792.	2.1	11
17	Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. <i>Journal of Neuro-Oncology</i> , 2018, 139, 307-322.	1.4	2
18	Pediatric low-grade gliomas can be molecularly stratified for risk. <i>Acta Neuropathologica</i> , 2018, 136, 641-655.	3.9	36

#	ARTICLE	IF	CITATIONS
19	The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. <i>Laboratory Investigation</i> , 2017, 97, 946-961.	1.7	24
20	Adult IDH wild-type lower-grade gliomas should be further stratified. <i>Neuro-Oncology</i> , 2017, 19, 1327-1337.	0.6	177
21	An Unusual Combination of Mirror-Image Dextrocardia with Familial Medulloblastoma: Is There a Histogenetic Relationship?. <i>World Neurosurgery</i> , 2017, 107, 860-867.	0.7	0
22	Dual degradation signals destruct GLI1: AMPK inhibits GLI1 through \hat{I}^2 -TrCP-mediated proteasome degradation. <i>Oncotarget</i> , 2017, 8, 49869-49881.	0.8	20
23	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. <i>Oncotarget</i> , 2016, 7, 64615-64630.	0.8	22
24	Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation. <i>Medical Oncology</i> , 2016, 33, 99.	1.2	10
25	Biomarker-based prognostic stratification of young adult glioblastoma. <i>Oncotarget</i> , 2016, 7, 5030-5041.	0.8	45
26	Combination genetic signature stratifies lower-grade gliomas better than histological grade. <i>Oncotarget</i> , 2015, 6, 20885-20901.	0.8	42
27	$\langle \text{sc} \rangle \text{miR} \langle / \text{sc} \rangle \hat{\alpha} \hat{\epsilon} 106 \text{b}$ is overexpressed in medulloblastomas and interacts directly with $\langle \text{sc} \rangle \text{PTEN} \langle / \text{sc} \rangle$. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 145-164.	1.8	37
28	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. <i>Modern Pathology</i> , 2015, 28, 177-186.	2.9	107
29	CRMP1 Inhibits Proliferation of Medulloblastoma and Is Regulated by HMGA1. <i>PLoS ONE</i> , 2015, 10, e0127910.	1.1	13
30	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. <i>Modern Pathology</i> , 2014, 27, 332-342.	2.9	45
31	Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e99490.	1.1	24
32	$\langle \text{sc} \rangle \text{MiR} \langle / \text{sc} \rangle \hat{\alpha} \hat{\epsilon} 383$ is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 ($\langle \text{sc} \rangle \text{PRDX3} \langle / \text{sc} \rangle$). <i>Brain Pathology</i> , 2013, 23, 413-425.	2.1	71
33	$\langle \text{sc} \rangle \text{MIR} \langle / \text{sc} \rangle \hat{\alpha} \hat{\epsilon} 137$ Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets $\langle \text{sc} \rangle \text{CSE1L} \langle / \text{sc} \rangle$. <i>Brain Pathology</i> , 2013, 23, 426-439.	2.1	39
34	Signaling pathway and molecular subgroups of medulloblastoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 1211-22.	0.5	18